ImmunoCellular Therapeutics (OTCMKTS:IMUC) Stock Price Down 1.6%

Shares of ImmunoCellular Therapeutics, Ltd. (OTCMKTS:IMUCGet Rating) dropped 1.6% during trading on Tuesday . The company traded as low as $0.39 and last traded at $0.60. Approximately 3,605 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 8,034 shares. The stock had previously closed at $0.61.

ImmunoCellular Therapeutics Price Performance

The stock’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.37.

ImmunoCellular Therapeutics Company Profile

(Get Rating)

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis.

Further Reading

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.